ArticleBMC cancer2026
NLR-based nomogram predicts survival in hepatocellular carcinoma treated with TACE plus targeted immunotherapy.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pre-TACE CK-MB/CK Ratio as an Independent Prognostic Biomarker in Advanced Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe neutrophil-to-lymphocyte ratio (NLR) has emerged as a potential prognostic biomarker in hepatocellular carcinoma (HCC), but its predictive value in patients with unresectable HCC receiving transarterial chemoembolization (TACE) combined with targeted agents and immune checkpoint inhibitors remains unclear. This study aimed to evaluate the prognostic significance of NLR in this setting and to develop individualized nomograms for predicting overall survival (OS) and progression-free survival (PFS).
methodsThis retrospective real-world cohort consecutively enrolled 148 patients who received TACE combined with molecular targeted agents and immune checkpoint inhibitors between May 2020 and December 2023. OS and PFS were estimated using Kaplan-Meier methods and compared by log-rank test. Prognostic factors were examined using Cox regression. Nomograms incorporating NLR and key clinicopathological variables were constructed, and model performance was assessed using time-dependent area under the curve (AUC) and concordance index (C-index).
resultsThe cohort was predominantly male (89.9%), and most patients had Barcelona Clinic Liver Cancer stage B/C disease (86.5%); portal vein tumor thrombus was present in 41.2%. The objective response rate was 47.3% by modified Response Evaluation Criteria in Solid Tumors, with a disease control rate of 89.9%. NLR independently predicted OS (HR 1.156, P = 0.013) and PFS (HR 1.165, P = 0.010). Using NLR cut-off of 2.49, patients with NLR ≥ 2.49 had significantly worse OS and PFS than those with NLR < 2.49 (both P < 0.001). NLR-based nomograms incorporating alpha-fetoprotein, Child-Pugh classification, and portal vein tumor thrombus showed moderate discrimination, with 0.5-year AUCs of 0.846 (95% CI, 0.734-0.958) for OS and 0.729 (95% CI, 0.621-0.838) for PFS.
conclusionNLR is a readily available biomarker that provides independent prognostic information in HCC patients receiving triple therapy. Nomograms may improve individualized risk stratification and facilitate treatment optimization in routine practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.